Source:http://linkedlifedata.com/resource/pubmed/id/10694294
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2000-3-2
|
| pubmed:abstractText |
An open study was conducted to identify and investigate dermatomyositis patients who benefit from IVIG treatment, based on dermatological criteria, myositis-related symptoms and immune/inflammatory parameters. 19 patients (16 females and three males, ages 31-84) suffered from dermatomyositis, and 4/19 patients had paraneoplastic dermatomyositis. We monitored the disease activity by documenting the clinical symptoms, recording muscle-related parameters (electromyography, serum creatine kinase, histopathology), and by determining circulating autoantibodies and serum levels of IL-6, sIL-2R, sTNF-a-R, sICAM-1, and sCD8. 7/19 patients responded to IVIG. They had severe skin but only moderate muscle involvement, no autoantibodies, and no malignancy. IVIG-nonresponders had severe skin and muscle disease, concomitant with autoantibodies and/or malignancy. sIL-2R levels were initially elevated in all patients but reverted to normal in IVIG-responders only. Creatine kinase-levels and other parameters did not correlate with disease activity and/or treatment response. IVIG is effective in selected dermatomyositis patients. sIL-2R serum levels appear to be useful predictors of IVIG-induced treatment response and disease activity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD8,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Creatine Kinase,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins, Intravenous,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1167-1122
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
29-35
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10694294-Adult,
pubmed-meshheading:10694294-Aged,
pubmed-meshheading:10694294-Aged, 80 and over,
pubmed-meshheading:10694294-Antigens, CD8,
pubmed-meshheading:10694294-Autoantibodies,
pubmed-meshheading:10694294-Creatine Kinase,
pubmed-meshheading:10694294-Dermatomyositis,
pubmed-meshheading:10694294-Electromyography,
pubmed-meshheading:10694294-Female,
pubmed-meshheading:10694294-Humans,
pubmed-meshheading:10694294-Immunoglobulins, Intravenous,
pubmed-meshheading:10694294-Intercellular Adhesion Molecule-1,
pubmed-meshheading:10694294-Interleukin-6,
pubmed-meshheading:10694294-Male,
pubmed-meshheading:10694294-Middle Aged,
pubmed-meshheading:10694294-Paraneoplastic Syndromes,
pubmed-meshheading:10694294-Receptors, Interleukin-2,
pubmed-meshheading:10694294-Receptors, Tumor Necrosis Factor
|
| pubmed:articleTitle |
High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
|
| pubmed:affiliation |
Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, University of Vienna, Austria. beatrice.volc@akh-wien.ac.at
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|